Soligenix opened lower at $0.31, compared with its previous close of $0.32. In the last trading session, the stock traded between $0.31 and $0.34. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Soligenix is now worth
$ 0.15
Resulting in a loss of
$ 99.85 (99.85%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
No analyst rating data available.
Markets Today
Today's Change
+$0.00 (+0.84%)
Day High
$0.34
Day Low
$0.31
Day Open
$0.31
Prev Close
$0.32
Volume
2,01,749
1W Return
-8.73%
1M Return
-8.22%
3M Return
-15.18%
6M Return
15.67%
1Y Return
-77.18%
Fundamentals
Market Cap ($ Mn)
8
PE Ratio
-
PB Ratio
1.23
PEG Ratio
-
ROE
-246.78%
ROCE
-254.77%
EPS (TTM)
$-0.09
Investment Returns
1 Week
-8.73%
1 Month
-8.22%
3 Months
-15.18%
6 Months
15.67%
9 Months
-70.00%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
6Nov
Soligenix Q3FY26 Results: Net loss narrows 56% YoY to $1.1 million
Net loss narrowed to $1.1 million ($0.05 per share) from $2.5 million ($0.58 per share). Beat analyst consensus estimate of $(0.10) per share by 50%. R&D expenses dropped 75% to $0.4 million following FLASH2 trial termination. Cash and cash equivalents stand at $9.0 million, funding operations into Q2 2028. No revenue reported for the quarter ended September 30, 2026.
6 days ago
20Aug
RIOM market set for growth to 2036 as US leads 7MM demand
RIOM market expected to grow positively by 2036 in 7MM. US held largest market share in 2025 with highest Grade III cases. No specific therapies currently approved; care remains supportive. Pipeline includes Dusquetide, RRx-001, and MIT-001.
2mo ago
7Aug
Soligenix Q2 Results: EPS beats estimates by 20%
Soligenix delivered a better-than-expected Q2 with EPS of $(0.12), beating the $(0.15) estimate by 20%. The result shows an 85.37% YoY improvement over the $(0.82) loss previously recorded, signaling strong operational progress.
